title: Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses?
authors.affiliation: West Virginia University Health Science Center, Department of Urology, Morgantown 26506, USA.
authors.forename: D L
authors.initials: DL
authors.lastname: Lamm
authors.forename: A P
authors.initials: AP
authors.lastname: van der Meijden
authors.forename: H
authors.initials: H
authors.lastname: Akaza
authors.forename: C
authors.initials: C
authors.lastname: Brendler
authors.forename: P O
authors.initials: PO
authors.lastname: Hedlund
authors.forename: Y
authors.initials: Y
authors.lastname: Mizutani
authors.forename: T L
authors.initials: TL
authors.lastname: Ratliff
authors.forename: M R
authors.initials: MR
authors.lastname: Robinson
authors.forename: T
authors.initials: T
authors.lastname: Shinka
mesh_terms: D000283:Administration, Intravesical; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001500:BCG Vaccine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D018450:Disease Progression; D006801:Humans; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D001500:BCG Vaccine